NCT05532059View on ClinicalTrials.gov

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2028

Conditions
Advanced Cholangiocarcinoma
Interventions
DRUG

Lenvatinib, tislelizumab, gemcitabine and cisplatin

Lenvatinib, tislelizumab, gemcitabine and cisplatin

DRUG

gemcitabine and cisplatin

gemcitabine and cisplatin

Trial Locations (1)

310009

RECRUITING

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER